Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gut microbial postbiotics as potential therapeutics for lymphoma: Proteomics Insights of the synergistic effects of Nisin and Urolithin B against human lymphoma cells

ABSTRACT: Lymphoma remains a substantial global health concern, necessitating innovative therapeutic strategies. The emerging role of gut microbiota-derived metabolites, known as postbiotics, offers promising avenues for cancer treatment. This study evaluated the antiproliferative activities of various postbiotics, including Nisin (N) and urolithin B (UB), and their combinations against the human lymphoma cell line HKB-11. Systematically, the antiproliferative effects and underlying mechanisms were characterised using Alamar Blue assays, combination index (CI) analyses, ROS measurements, flow cytometry, and bottom-up proteomics analyses of combined and mono-treatments. Nisin and UB demonstrated significant antiproliferative activity with IC50 values of 1467 µM and 87.56 µM, respectively. Among other ratios, their combination at a ratio of 4:6 exhibited potent synergy (CI =0.09 at IC95), notably enhancing apoptosis (p < 0.0001) and modulating ROS levels. Proteomics analyses identified key protein alterations involved in lipid metabolism, mitochondrial function, cell cycle progression, and apoptosis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Lymphoma

SUBMITTER: Muhammad Alsherbiny

LAB HEAD: Deep Bhuyan

PROVIDER: PXD063948 | Pride | 2025-07-19

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20250309_022151_250307_DB_AK_ALL.sne	Other
	250307_AK_10a.wiff	Wiff
	250307_AK_10a.wiff.scan	Wiff
	250307_AK_10b.wiff	Wiff
	250307_AK_10b.wiff.scan	Wiff

Items per page:

1 - 5 of 50

Similar Datasets

Unveiling Proteomic Responses to Combined Nisin and Urolithin B Treatment (7:3) in Lymphoma Cells

Project description:This study investigates the antiproliferative and pro-apoptotic effects of the postbiotics nisin and urolithin B (UB) on lymphoma cells, individually and in combination. Human Burkitt lymphoma (HKB-11) and Hs 313.T cell lines and normal stromal HS-5 cells were treated with nisin, UB, and nine different ratios of their combinations. A 7:3 ratio (nisin 5600 μM + UB 150 μM) demonstrated synergistic anticancer activity with minimal cytotoxicity to normal cells. Flow cytometry confirmed that UB alone was the most potent inducer of apoptosis (p < 0.0001), followed by the 7:3 combination, significantly improving nisin’s apoptotic effect. Reactive oxygen species (ROS) assays demonstrated that nisin triggered concentration-dependent ROS production, whereas UB modulated this effect when combined, thereby reducing oxidative stress. Label-free proteomic analysis revealed distinct expression profiles. Nisin treatment upregulated oxidative stress-related proteins (HBA1, CYC1) and suppressed cell cycle proteins (CDK1, CCNB1), indicating mitotic inhibition. UB altered mitochondrial and epigenetic regulators (CYCS, DNMT1), and the combination therapy significantly downregulated ribosomal proteins (RPS14, RPL11, RPS27) and TP53, suggesting that ribosomal stress mediates antiproliferative effects. Synergy analysis confirmed combination index (CI) values <1 at 4:6 and 7:3 ratios, validating synergistic interactions.

2025-07-30 | PXD063952 | Pride

Combination Therapy with Nisin, Urolithin B, and Vincristine Exhibits Synergistic Antiproliferative and Pro-Apoptotic Effects Against Human Lymphoma Cells: Evidence From Proteomics

Project description:This study investigates the synergistic antitumor efficacy of a triple combination therapy—Nisin (N), Urolithin B (UB), and Vincristine (Vinc)—against human HBK11 lymphoma cells, with an emphasis on proteomic mechanisms of action. The findings elucidate the molecular underpinnings of this novel combination and underscore the potential of postbiotics as adjuvants to conventional chemotherapy, offering a mechanistically informed strategy for improved lymphoma treatment.

2025-09-19 | PXD065631 | Pride

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Project description:Diffuse large B-cell lymphoma (DLBCL) is a disease with heterogeneous outcome. Stromal signatures have been correlated to survival in DLBCL. Their use, however, is hampered by the lack of assays for formalin-fixed paraffin-embedded material (FFPE). We constructed a lymphoma-associated macrophage interaction signature (LAMIS) interrogating features of the microenvironment using a NanoString assay applicable to FFPE. The clinical impact of the signature could be validated in a cohort of 466 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Patients with high expression of the signature (LAMIShigh) had shorter EFS, PFS, and OS. Multivariate analyses revealed independence from IPI factors in EFS (HR 1.7, 95% CI 1.2–2.4, p-value = 0.001), PFS (HR 1.8, 95% CI 1.2–2.5, p-value = 0.001) and OS (HR 1.8, 95% CI 1.3–2.7, p-value = 0.001). Multivariate analyses adjusted for the IPI factors showed the signature to be independent from COO, MYC rearrangements and double expresser status (DE). LAMIShigh and simultaneous DE status characterized a patient subgroup with dismal prognosis and early relapse. Our data underline the importance of the microenvironment in prognosis. Combined analysis of stromal features, the IPI and DE may provide a new rationale for targeted therapy.

2025-09-06 | GSE280418 | GEO

Lymphoma subpopulations in an Anaplastic Large Cell Lymphoma mouse model

Project description:To examine the existence of lymphoma initiating cells, we used an anaplastic large cell lymphoma mouse model. Established NPM-ALK+ lymphomas contained a heterogeneous cell composition ranging from mature T-cells to undifferentiated hematopoietic stem cells. To investigate the underlying mechanisms and activated pathways of lymphoma initiating cells we used gene expression analyses. These analyses unmasked stem-cell-like transcriptional regulation exclusively of the DN3/DN4 lymphoma T-cell subpopulation.

2020-05-26 | GSE132267 | GEO

The post-biotic sodium butyrate synergizes the antiproliferative effects of dexamethasone against the AGS gastric adenocarcinoma cell

Project description:This research explores the antiproliferative effects of short-chain fatty acid (SCFA) salts (magnesium acetate, sodium propionate, and sodium butyrate) on AGS gastric adenocarcinoma cells. Sodium butyrate (NaB) exhibited the most significant inhibitory impact. The study investigated synergistic interactions between NaB and the drug dexamethasone (Dex) using a combination index model. Dex and NaB at a 2:8 ratio showed strong synergy, surpassing mono treatments in inhibitory activity. NaB induced pro-oxidative effects, countered by Dex in combination. Cell population analyses indicated a shift towards apoptosis with Dex, NaB, and their combination. Proteomic analysis revealed downregulation of the oncogene TNS4, suggesting a potential mechanism for antiproliferative effects. These findings suggest NaB as a potential adjuvant therapy with Dex, prompting further exploration of combination therapies and molecular mechanisms, emphasizing the potential application of these postbiotics in gastric cancer treatment.

2024-02-21 | PXD048617 | Pride

Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells

Project description:Short-chain fatty acids (SCFAs) are microbial metabolites, also known as postbiotics, produced by the gut microbiotame, playing essential rolesessential in maintaining gut health and exerting potential anticancer effects. This study investigates the antiproliferative effects of short-chain fatty acids (SCFAs) salts—magnesium acetate (A), sodium propionate (P), and sodium butyrate (B)—and their combinations with dexamethasone (Dex) in AGS gastric adenocarcinoma cells.

2025-07-30 | PXD061822 | Pride

Identification of genes involved in apoptosis-induced by cold atmospheric pressure plasma in human lymphoma U937 cells

Project description:Cold atmospheric pressure plasma (CAP) is known as a source of biologically active agents, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS). Recent medical investigations have focused on applying CAP to cancer treatment. There is also growing evidence that exposure of cells to CAP or CAP-activated medium induces apoptosis in cancer cells, and ROS and/or RNS are considered to be effective agents to CAP-induced apoptosis. More recently, we demonstrated that Ar-CAP or Ar containing 2.5 % of N2 (Ar-N2-CAP) significantly induced apoptosis in human lymphoma U937 cells. However, a detailed molecular mechanism underling the induction of apoptosis by CAP in cancer cells is unclear. In the present study, to identify genes involved in the induction of apoptosis by CAP in human lymphoma U937 cells, global-scale gene expression analysis was performed using a GeneChipÂ® system. Human lymphoma U937 cells were treated with Ar-CAP or Ar-N2-CAP. Total RNA samples were prepared from the cells, and quality of the RNA was analyzed using a Bioanalyzer 2100. Gene expression was analyzed by an Affymetrix GeneChipÂ® system with a Human Genome U133-plus 2.0 array. Sample preparation for array hybridization was carried out as described in the manufacturerâs instructions.

2015-12-15 | E-GEOD-76022 | biostudies-arrayexpress

Pharmacological profiling of a berbamine derivative for lymphoma treatment

Project description:Ca2+/calmodulin-dependent protein kinase II gamma (CAMKIIγ) has been identified as a potential target for treating cancer. Based on our previous study of Berbamine (BBM) as a CAMKIIγ inhibitor, we have synthesized a new BBM derivative termed PA4. Compared to BBM, PA4 showed improved potency and specificity, and was more cytotoxic against lymphoma and leukemia compared to other types of cancer. In addition to indirectly targeting c-Myc protein stability, we demonstrated that its cytotoxic effects were also mediated via increased ROS production in lymphoma cells. PA4 significantly impeded tumor growth in vivo in a xenograft T-cell lymphoma (TCL) mouse model. Pharmacokinetics studies depicted quick absorption into plasma after oral administration with a max concentration of 1680 ± 479 ng/mL at 5.33 ± 2.31 hr. The calculated oral absolute bioavailability was 34.1%. Toxicity assessment of PA4 showed that the therapeutic window used in our experiments was safe for future development. Given its efficacy, safety, and favorable pharmacokinetic profile, PA4 is a potential lead candidate for treating lymphoma.

2024-02-14 | GSE245491 | GEO

T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma

Project description:Global proteomics profiling of anaplastic large cell lymphoma cell lines DEL, SU-DHL-1 (ALK+), Mac-1, Mac-2A (ALK-) as well as Hodgkin lymphoma cell lines L-428, L-540, L-1236 and HDLM-2.

2022-08-12 | PXD031907 | Pride

Transgenic Eµ-myc mouse lymphoma expression data for training dataset

Project description:We used gene expression data from Eµ-myc mouse lymphomas to perform unsupervised analyses that identified two lymphoma subgroups. We also used this data to develop a genomic signature to classify new lymphomas. When Eµ-myc mice had evidence of lymphoma and/or ill appearance, they were humanely sacrificed and dissected. Lymphoma tissue was obtained and flash frozen in liquid nitrogen. Later, lymphoma tissue was homogenized, and RNA was extracted. Gene expression microarrays were performed with the isolated RNA.

2014-09-10 | E-GEOD-40756 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data